Strategic Context

The Radiopharmaceuticals Third-Party Logistics Market was valued at USD 848.9 million in 2025, with a 2026 estimate of USD 973.3 million and a forecast of USD 2,988.6 million by 2034. At a CAGR of 15.1%, growth is linked to nuclear medicine in oncology diagnostics and therapeutics, rising demand for radiopharmaceutical cold chain services, and expanding healthcare 3PL outsourcing. Expansion is also tied to rising cancer incidence, growing use of nuclear imaging tests, and significant investment in theragnostic and precision medicine.

Theranostics and Precision Oncology

Radiotheranostics is driving high-margin logistics demand as targeted radionuclide therapies and precision oncology applications spread across healthcare systems. Personalized drug delivery relies on radioactive substances such as Lu-177 and Ga-68, and the short half-life of these isotopes raises demand for logistics services. In September 2025, Memorial Sloan Kettering Cancer Center highlighted advances in targeted imaging and radiotherapy treatments. In April 2026, Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to co-develop and commercialize radiopharmaceutical therapies for solid tumors.

In March 2026, Aptamer Group entered an agreement with Radiopharmium Ltd to develop radiopharmaceuticals for cancer treatment. Growing theranostics adoption is also increasing demand for time-sensitive pharma logistics services.

AI and Integrated Platforms

AI-enabled logistics optimization is improving shipment visibility, routing plans, and delivery accuracy across radiopharmaceutical transportation networks. Predictive monitoring and analytics help logistics companies minimize isotope wastage and ensure effective delivery of nuclear medicines. AI-driven supply chain tools also provide inventory visibility. The market is shifting toward integrated platforms that combine transportation, packaging, monitoring, and compliance management in a unified healthcare logistics ecosystem.

Regulation and Cost Structure

Compliance is a defining cost factor. Providers must align packaging technology, radiation protection, and cold chain capability with IAEA and FDA transport regulations, which is why regulatory compliance services form a distinct service category. According to the report, transportation represents about 40% of total logistics cost, followed by specialized packaging at 20%, regulatory compliance and insurance and risk coverage at 15% each, and monitoring and tracking at 10%. Domestic shipments average USD 500 to 2,000 per delivery, while international shipments range from USD 2,000 to 10,000 or more.

Cost of Delay and Supply Dynamics

Delay carries a measurable cost. A one-hour delivery delay can result in approximately 10–20% isotope value loss from radioactive decay, while a four-hour delay can lead to nearly 40–60% value erosion for short half-life products. Regional isotope supply imbalance adds complexity: North America shows a balanced supply-demand environment, Europe is supply constrained because of reactor dependency, and Asia Pacific faces a significant isotope demand deficit. Because isotopes decay, even short delays in transit erode value, so providers compete on speed, geographic coverage, and shipment visibility.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/radiopharmaceuticals-third-party-logistics-market 

Regional Developments

North America dominated with a 41.6% share in 2025; in May 2026, Bayer reported favorable Phase III outcomes for its PET tracer I-124 Evuzamitide in cardiac amyloidosis detection at several US sites. Europe held about 28%, and the European Nuclear Society notes that nuclear medicine supports diagnosis and treatment for more than 10 million patients annually across Europe. In December 2024, China announced a commercial reactor-based isotope production device for continuous production of Lu-177, Strontium-89, and Yttrium-90. Brazil, Saudi Arabia, and the UAE are investing in cancer treatment facilities and radiopharmaceutical transport. The outlook remains strong due to increasing investment in artificial intelligence, decentralized isotope production, and smart cold chain systems. Latin America and the Middle East and Africa are growing at a constant pace as medical advances and acceptance of nuclear medicine increase.

Key Players

• Agility Public Warehousing Company K.S.C.
• AIT Worldwide Logistics, Inc.
• Alliance Healthcare
• AmerisourceBergen Corporation
• Cardinal Health, Inc.
• CEVA Logistics
• Curium Pharma LLC
• Deutsche Post DHL Group
• FedEx Corporation
• Kuehne + Nagel International AG
• McKesson Corporation
• SF Express Co., Ltd.
• UPS Supply Chain Solutions, Inc.
• United Parcel Service of America, Inc.

Conclusion

Success in the Radiopharmaceuticals Third-Party Logistics Market will depend on managing compliance, controlling delay risk, and adopting smarter digital tools. As theranostics expands and the market moves toward USD 2,988.6 million by 2034, logistics providers that integrate transportation, packaging, monitoring, and compliance will be better prepared to meet the needs of healthcare customers.

More Trending Latest Reports By Polaris Market Research:

Mushroom Market

Hyper Cars Market

Mycelium Market

Refurbished Medical Imaging Equipment Market

Power Transformer Market

Brain Implants Market

Brain Implants Market

Mycelium Market

Healthcare Supply Chain BPO Market